More on Cas13 from Feng Zhangs Team:
RNAY editing delivery using ultracompact versions of Cas13. Zhangâ€™s team identified a subfamily of Cas13, known as Cas13bt that are roughly half the size of other enzymes in the family and can fit neatly into an AAV package
The size of the enzymes are a crucial factor in the ability to deliver the genetic payload hence the importance of Zhangâ€™s lab latest discovery.
I will add, having one person be CEO, President, and Director of the Board is unsustainable for a company with big long term plans. Iâ€™m curious how that changes or progresses over the coming years.
Price predictions for today? I hope it hold above 60 today. I think weâ€™ll see green tomorrow - new month
Seems like a shake out of traders taking money off the table. Good news $95, Bad news $35. Im in!
Big news this week one way or the other. Place you bets!!!
8/16/2021 Jefferies Group LLC 43,400 2,370,000 +5,360.8% $1,342.00 (short interest change)
I am looking forward to next week and beyond, and hope all of us longs enjoy the success of the long-awaited results. Good weekend to all.
This is setting up technically and fundamentally for a big sustainable run. Much better follow through happening with new management.
Im a happy Puppy just bought 100 @61.80.Load up Puppies
Shake out , onward MARCH .....
Short positions fell by 1 million shares in the last 15 days and over 3 million shares in the last 45 days to a multi-year low of 7,497,370 shares short. This tells me the smart money consensus is there are just too many catalysts on the horizon for them to remain short. I still maintain next week around the 1st we will see a steady rise in share price until we hear the EDIT-101 data.
More on Cas13b and its significance - work from Feng Zhangs lab:
Cas13bt, tiny version of Cas13b, can be used to create RNA editors. Theyre small enough to fit into a single AAV for in-vivo CRISPR gene-editing delivery.
I never understood the logic of a crisis taking the whole market down. What does gene editing have to do with an explosion in Kabul? Anyway, its part of the game if you have cash you have a buying opportunity
It has been 45 days since the last motion was presented and denied by the US Patent Trial Appeals Board (PTAB), which is the longest period of silence in this case so far, so I am assuming the panel of judges is deep into their final review of facts in the current CVC vs. Broad et al; CRISPR interference case that began June, 24th, 2019, to determine priority.
I am going to go out on a limb and predict the final decision will be rendered within 30 days, sometime around the time the Editas 101 data is announced.
Weird price action in CRISPR stocks this morning, they are all over the place.
Since our ceo will speak I dont expect data to be discussed. And as the topic is treating rare diseases, maybe he will give timeline about IND. They promised by the end of the year. Could be now
There is a big disconnect between the NASDAQ (up 141 points) and most gene-editing companies today.
Should not be under 100 at this point. I expect with 14% short interest, Editas will rise to 88 or so by September clinical update if EDIT follows the NTLA model. Hard to say as EDIT is differentiated with SLEEK
Find us at the office
Exel- Frazzitta street no. 61, 44925 Kingston, Norfolk Island
Give us a ring
+23 274 947 142
Mon - Fri, 10:00-21:00